Fig. 4From: TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapyConcomitant TP53 mutation and MIR34A methylation “double-hit” associated with poorer progression free survival in CCT-treated PCNSL patients. Kaplan-Meier plot of 52/57 PCNSL patients, of which the 8 patients with “double-hit” TP53 mutation and MIR34A promoter methylation had a significantly poorer PFS. P = 0.0070Back to article page